speb/financial-data huggingface dataset:
GENO.OL cash_flow (annual, 2024-12-31) — Taxes Refund Paid: -30967000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Assets: 1316261000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Capitalization: 756796000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Debt: 275231000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 718389000.00
GENO.OL income_statement (annual, 2024-12-31) — Total Expenses: 893303000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 597872000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 607896000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 171482000.00
GENO.OL income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 68171000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Total Tax Payable: 33015000.00
GENO.OL income_statement (annual, 2024-12-31) — Total Unusual Items: 0.00
GENO.OL income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
GENO.OL balance_sheet (annual, 2024-12-31) — Tradeand Other Payables Non Current: 5542000.00
GENO.OL balance_sheet (annual, 2024-12-31) — Treasury Stock: 0.00
GENO.OL balance_sheet (annual, 2024-12-31) — Working Capital: 281975000.00
GENO.OL income_statement (quarterly, 2025-03-31) — +Operating Expense: 154526000.00
GENO.OL income_statement (quarterly, 2025-03-31) — +Total Revenue: 341664000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Basic Average Shares: 192245306.00
GENO.OL income_statement (quarterly, 2025-03-31) — Basic EPS: 0.23
GENO.OL cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 281632000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -35210000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -40000000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Change In Inventory: 6827000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: 44682000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: 60704000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Change In Payable: 9327000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Change In Receivables: -51233000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 70307000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Changes In Cash: 50655000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 0.00
GENO.OL income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 130407000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Deferred Tax: 15298000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Depreciation: 17011000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 17011000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 17011000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 17011000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 192245306.00
GENO.OL income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.23
GENO.OL income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 44032000.00
GENO.OL income_statement (quarterly, 2025-03-31) — EBIT: 63208000.00
GENO.OL income_statement (quarterly, 2025-03-31) — EBITDA: 80219000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 617000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — End Cash Position: 332904000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -49491000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 86953000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of PPE: -1424000.00
GENO.OL income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 8220000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Gross Profit: 211257000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Interest Expense: 3878000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 3878000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Interest Income: 3310000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 3310000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Interest Paid Cfo: -4225000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Interest Received Cfi: 1008000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -22017000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -4731000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Business Purchase And Sale: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 902000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Income: 44032000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 44032000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 44032000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 44032000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 44032000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 44032000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 44032000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -4453000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Interest Income: -915000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -4731000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -4731000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -915000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 12185000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -30757000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 80219000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Normalized Income: 44032000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 122163000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Operating Income: 56731000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Operating Revenue: 341664000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 915000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 4416000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 22848000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
GENO.OL income_statement (quarterly, 2025-03-31) — Pretax Income: 59330000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Provisionand Write Offof Assets: 14000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Purchase Of Business: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -4453000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -30757000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 130407000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 17011000.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -4731000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Research And Development: 2624000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 3458000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Selling General And Administration: 11678000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
GENO.OL cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 0.00
GENO.OL income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
GENO.OL income_statement (quarterly, 2025-03-31) — Tax Provision: 15298000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.26
GENO.OL cash_flow (quarterly, 2025-03-31) — Taxes Refund Paid: -20667000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Total Expenses: 284933000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 61147000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Total Other Finance Cost: 347000.00
GENO.OL income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
GENO.OL income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
GENO.OL income_statement (annual, 2025-12-31) — +Operating Expense: 639741000.00
GENO.OL income_statement (annual, 2025-12-31) — +Total Revenue: 1280410000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Accounts Payable: 45652000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Accounts Receivable: 180048000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -129021000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 549015000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -631000.00
GENO.OL income_statement (annual, 2025-12-31) — Basic Average Shares: 192245306.00
GENO.OL income_statement (annual, 2025-12-31) — Basic EPS: 0.86
GENO.OL cash_flow (annual, 2025-12-31) — Beginning Cash Position: 281632000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 80347000.00
GENO.OL cash_flow (annual, 2025-12-31) — Capital Expenditure: -36569000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 87839000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Capital Stock: 5727000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 341356000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 347693000.00
GENO.OL cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -40000000.00
GENO.OL cash_flow (annual, 2025-12-31) — Change In Inventory: -9285000.00
GENO.OL cash_flow (annual, 2025-12-31) — Change In Other Current Assets: 70471000.00
GENO.OL cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -1895000.00
GENO.OL cash_flow (annual, 2025-12-31) — Change In Payable: -6497000.00
GENO.OL cash_flow (annual, 2025-12-31) — Change In Receivables: -42108000.00
GENO.OL cash_flow (annual, 2025-12-31) — Change In Working Capital: 10686000.00
GENO.OL cash_flow (annual, 2025-12-31) — Changes In Cash: 64682000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Common Stock: 5727000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Common Stock Equity: 707843000.00
GENO.OL cash_flow (annual, 2025-12-31) — Common Stock Issuance: 4602000.00
GENO.OL income_statement (annual, 2025-12-31) — Cost Of Revenue: 459060000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Current Assets: 825819000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 17490000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Current Debt: 70964000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 88454000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Current Liabilities: 533384000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Current Provisions: 1195000.00
GENO.OL cash_flow (annual, 2025-12-31) — Deferred Tax: 22171000.00
GENO.OL cash_flow (annual, 2025-12-31) — Depreciation: 64818000.00
GENO.OL cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 64818000.00
GENO.OL income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 64818000.00
GENO.OL income_statement (annual, 2025-12-31) — Depreciation Income Statement: 64818000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Derivative Product Liabilities: 0.00
GENO.OL income_statement (annual, 2025-12-31) — Diluted Average Shares: 192245306.00
GENO.OL income_statement (annual, 2025-12-31) — Diluted EPS: 0.86
GENO.OL income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: 165081000.00
GENO.OL income_statement (annual, 2025-12-31) — EBIT: 195755000.00
GENO.OL income_statement (annual, 2025-12-31) — EBITDA: 260573000.00
GENO.OL cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -4958000.00
GENO.OL cash_flow (annual, 2025-12-31) — End Cash Position: 341356000.00
GENO.OL cash_flow (annual, 2025-12-31) — Financing Cash Flow: -167203000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Finished Goods: 86556000.00
GENO.OL cash_flow (annual, 2025-12-31) — Free Cash Flow: 171847000.00
GENO.OL cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: -4027000.00
GENO.OL income_statement (annual, 2025-12-31) — General And Administrative Expense: 33200000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Goodwill: 110393000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 271867000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 180679000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Gross PPE: 340668000.00
GENO.OL income_statement (annual, 2025-12-31) — Gross Profit: 821350000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Hedging Assets Current: 0.00
GENO.OL income_statement (annual, 2025-12-31) — Interest Expense: 8503000.00
GENO.OL income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 8503000.00
GENO.OL income_statement (annual, 2025-12-31) — Interest Income: 5127000.00
GENO.OL income_statement (annual, 2025-12-31) — Interest Income Non Operating: 5127000.00
GENO.OL cash_flow (annual, 2025-12-31) — Interest Paid Cfo: -15490000.00
GENO.OL cash_flow (annual, 2025-12-31) — Interest Received Cfi: 5127000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Inventories Adjustments Allowances: -12862000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Inventory: 243819000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Invested Capital: 778807000.00
GENO.OL cash_flow (annual, 2025-12-31) — Investing Cash Flow: 23469000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Investmentin Financial Assets: 0.00
GENO.OL balance_sheet (annual, 2025-12-31) — Investmentsin Associatesat Cost: 0.00
GENO.OL cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 4602000.00
GENO.OL cash_flow (annual, 2025-12-31) — Issuance Of Debt: 34269000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Land And Improvements: 80087000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 70349000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Long Term Debt: 0.00
GENO.OL balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 70349000.00
GENO.OL cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 34269000.00
GENO.OL cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -146017000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 0.00
GENO.OL balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 180234000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -170000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 4602000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Income: 165081000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Income Common Stockholders: 165081000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Income Continuous Operations: 165081000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 165081000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 165081000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 165081000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: 165081000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -678000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Interest Income: -10363000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -111748000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -111748000.00
GENO.OL income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -10363000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net Other Investing Changes: 55081000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Net PPE: 211647000.00
GENO.OL cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -35891000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 435976000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 0.00
GENO.OL balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 42108000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 40009000.00
GENO.OL income_statement (annual, 2025-12-31) — Normalized EBITDA: 256546000.00
GENO.OL income_statement (annual, 2025-12-31) — Normalized Income: 161529186.00
GENO.OL cash_flow (annual, 2025-12-31) — Operating Cash Flow: 208416000.00
GENO.OL income_statement (annual, 2025-12-31) — Operating Income: 181609000.00
GENO.OL income_statement (annual, 2025-12-31) — Operating Revenue: 1280410000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 192245306.00
GENO.OL balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 103586000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 161474000.00
GENO.OL cash_flow (annual, 2025-12-31) — Other Non Cash Items: 10454000.00
GENO.OL income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 15108000.00
GENO.OL income_statement (annual, 2025-12-31) — Other Operating Expenses: 90238000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Other Payable: 3087000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Other Receivables: 16606000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 6337000.00
GENO.OL income_statement (annual, 2025-12-31) — Other Special Charges: -4027000.00
GENO.OL income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
GENO.OL balance_sheet (annual, 2025-12-31) — Payables: 110491000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Prepaid Assets: 35598000.00
GENO.OL income_statement (annual, 2025-12-31) — Pretax Income: 187252000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Properties: 0.00
GENO.OL cash_flow (annual, 2025-12-31) — Provisionand Write Offof Assets: 275000.00
GENO.OL cash_flow (annual, 2025-12-31) — Purchase Of Business: -170000.00
GENO.OL cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -678000.00
GENO.OL cash_flow (annual, 2025-12-31) — Purchase Of PPE: -35891000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Raw Materials: 139537000.00
GENO.OL income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 459060000.00
GENO.OL income_statement (annual, 2025-12-31) — Reconciled Depreciation: 64818000.00
GENO.OL cash_flow (annual, 2025-12-31) — Repayment Of Debt: -146017000.00
GENO.OL income_statement (annual, 2025-12-31) — Research And Development: 15491000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Retained Earnings: 175481000.00
GENO.OL cash_flow (annual, 2025-12-31) — Sale Of PPE: 55081000.00
GENO.OL income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 19703000.00
GENO.OL income_statement (annual, 2025-12-31) — Selling General And Administration: 52903000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Share Issued: 192245306.00
GENO.OL income_statement (annual, 2025-12-31) — Special Income Charges: 4027000.00
GENO.OL cash_flow (annual, 2025-12-31) — Stock Based Compensation: 495000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Stockholders Equity: 707843000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Tangible Book Value: 435976000.00
GENO.OL income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 475186.00
GENO.OL income_statement (annual, 2025-12-31) — Tax Provision: 22171000.00
GENO.OL income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.12
GENO.OL balance_sheet (annual, 2025-12-31) — Taxes Receivable: 2055000.00
GENO.OL cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -46047000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Assets: 1352413000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Capitalization: 707843000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Debt: 158803000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 707843000.00
GENO.OL income_statement (annual, 2025-12-31) — Total Expenses: 1098801000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 644570000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 526594000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 111186000.00
GENO.OL income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 185458000.00
GENO.OL income_statement (annual, 2025-12-31) — Total Other Finance Cost: 6987000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Total Tax Payable: 61752000.00
GENO.OL income_statement (annual, 2025-12-31) — Total Unusual Items: 4027000.00
GENO.OL income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: 4027000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Treasury Stock: 98984000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Work In Process: 30588000.00
GENO.OL balance_sheet (annual, 2025-12-31) — Working Capital: 292435000.00
GENO.OL income_statement (quarterly, 2026-03-31) — +Operating Expense: 167774000.00
GENO.OL income_statement (quarterly, 2026-03-31) — +Total Revenue: 324015000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 58126000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 213667000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 1018637000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Basic Average Shares: 165125245.00
GENO.OL income_statement (quarterly, 2026-03-31) — Basic EPS: 0.16
GENO.OL cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 341356000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 75042000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -19076000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 83018000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Capital Stock: 6536000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 840130000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 840130000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Cash Dividends Paid: -19656000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Change In Inventory: 5001000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Change In Other Current Assets: 44583000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -13595000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Change In Payable: 12474000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Change In Receivables: -41773000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 6690000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Changes In Cash: 494699000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Common Stock: 6536000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 1165142000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 500000000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 106607000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Current Assets: 1355028000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 17109000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Current Debt: 80019000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 97128000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 592551000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Current Provisions: 1187000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Deferred Tax: 16136000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Depreciation: 15699000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 15699000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 15699000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 15699000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 165655064.00
GENO.OL income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.16
GENO.OL income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 25935000.00
GENO.OL income_statement (quarterly, 2026-03-31) — EBIT: 43752000.00
GENO.OL income_statement (quarterly, 2026-03-31) — EBITDA: 59451000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 4075000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — End Cash Position: 840130000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 484158000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Free Cash Flow: 19623000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: 4645000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Gain Loss On Sale Of PPE: -62000.00
GENO.OL income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 8404000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Goodwill: 106764000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 257451000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Gross PPE: 203384000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Gross Profit: 217408000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Interest Expense: 1681000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 1681000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Interest Income: 868000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 868000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Interest Paid Cfo: -1306000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Interest Received Cfi: 868000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Inventory: 238818000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1245161000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -28158000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Investmentsin Associatesat Cost: 10018000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 500000000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Issuance Of Debt: 80000000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 58767000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 65909000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 0.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 65909000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 80000000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -71700000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 10018000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 69575000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: 0.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 500000000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -857000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Income: 25935000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 25935000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 25935000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 25935000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 25935000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: 25935000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 25935000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: -4110000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Interest Income: -1164000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: -10018000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: 8300000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: 8300000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -1164000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: 68000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Net PPE: 203384000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -14966000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 907691000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 34330000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 37489000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 69825000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Normalized Income: 32330134.18
GENO.OL cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 38699000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Operating Income: 49634000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Operating Revenue: 324015000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 187612016.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 150687000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 1164000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 3118000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 22718000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Other Payable: 107498000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Other Receivables: 62413000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Other Special Charges: 5729000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Payables: 192438000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Pretax Income: 42071000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Provisionand Write Offof Assets: 160000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Purchase Of Business: 0.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: -4110000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -14966000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 106607000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 15699000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -71700000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Research And Development: 5339000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 181760000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 6894000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Selling General And Administration: 15298000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Share Issued: 192245306.00
GENO.OL income_statement (quarterly, 2026-03-31) — Special Income Charges: -5729000.00
GENO.OL cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 869000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 1165142000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 907691000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -3978865.82
GENO.OL income_statement (quarterly, 2026-03-31) — Tax Provision: 16136000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.38
GENO.OL cash_flow (quarterly, 2026-03-31) — Taxes Refund Paid: -30374000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Assets: 1861695000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 1165142000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Debt: 163037000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 1165142000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Total Expenses: 274381000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 696553000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 506667000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 104002000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: 47023000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Total Other Finance Cost: 351000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 26814000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Total Unusual Items: -10374000.00
GENO.OL income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -10374000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 4633290.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 97482000.00
GENO.OL balance_sheet (quarterly, 2026-03-31) — Working Capital: 762477000.00
GENT.OL income_statement (annual, 2021-12-31) — Basic Average Shares: 15415000.00
GENT.OL income_statement (annual, 2021-12-31) — Basic EPS: -1.61
GENT.OL cash_flow (annual, 2021-12-31) — Common Stock Issuance: 570000.00
GENT.OL income_statement (annual, 2021-12-31) — Depreciation And Amortization In Income Statement: 7351000.00
GENT.OL income_statement (annual, 2021-12-31) — Depreciation Income Statement: 7351000.00
GENT.OL income_statement (annual, 2021-12-31) — Diluted Average Shares: 15415000.00
GENT.OL income_statement (annual, 2021-12-31) — Diluted EPS: -1.61
GENT.OL cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 570000.00
GENT.OL cash_flow (annual, 2021-12-31) — Issuance Of Debt: 0.00
GENT.OL cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 0.00
GENT.OL cash_flow (annual, 2021-12-31) — Long Term Debt Payments: -3691000.00
GENT.OL cash_flow (annual, 2021-12-31) — Net Business Purchase And Sale: 0.00
GENT.OL cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 570000.00
GENT.OL cash_flow (annual, 2021-12-31) — Net Issuance Payments Of Debt: -3691000.00
GENT.OL cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: -3691000.00
GENT.OL balance_sheet (annual, 2021-12-31) — Other Equity Interest: 1000.00
GENT.OL income_statement (annual, 2021-12-31) — Other Operating Expenses: 38235000.00
GENT.OL income_statement (annual, 2021-12-31) — Rent And Landing Fees: 1432000.00
GENT.OL cash_flow (annual, 2021-12-31) — Repayment Of Debt: -3691000.00
GENT.OL cash_flow (annual, 2021-12-31) — Sale Of Business: 0.00
GENT.OL income_statement (annual, 2021-12-31) — Special Income Charges: 0.00
GENT.OL income_statement (annual, 2021-12-31) — Total Unusual Items: 0.00
GENT.OL income_statement (annual, 2021-12-31) — Total Unusual Items Excluding Goodwill: 0.00
GENT.OL income_statement (annual, 2022-12-31) — +Operating Expense: 72236000.00
GENT.OL income_statement (annual, 2022-12-31) — +Total Revenue: 101636000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Accounts Payable: 4443000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Accounts Receivable: 10063000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -24114000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 309104000.00
GENT.OL cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 3882000.00
GENT.OL income_statement (annual, 2022-12-31) — Basic Average Shares: 15422000.00
GENT.OL income_statement (annual, 2022-12-31) — Basic EPS: -1.53
GENT.OL cash_flow (annual, 2022-12-31) — Beginning Cash Position: 114936000.00
GENT.OL cash_flow (annual, 2022-12-31) — Capital Expenditure: -14666000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 15323000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Capital Stock: 1542000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 81599000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 81599000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Cash Equivalents: 2342000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Cash Financial: 79258000.00
GENT.OL cash_flow (annual, 2022-12-31) — Change In Inventory: -8765000.00
GENT.OL cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 8917000.00
GENT.OL cash_flow (annual, 2022-12-31) — Change In Payable: -532000.00
GENT.OL cash_flow (annual, 2022-12-31) — Change In Receivables: -3550000.00
GENT.OL cash_flow (annual, 2022-12-31) — Change In Working Capital: -3930000.00
GENT.OL cash_flow (annual, 2022-12-31) — Changes In Cash: -32943000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Common Stock: 1542000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Common Stock Equity: 154170000.00
GENT.OL cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
GENT.OL income_statement (annual, 2022-12-31) — Cost Of Revenue: 52635000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Current Assets: 139332000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 3699000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 3699000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Current Liabilities: 21996000.00
GENT.OL cash_flow (annual, 2022-12-31) — Depreciation: 6361000.00
GENT.OL cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 10243000.00
GENT.OL income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 10243000.00
GENT.OL income_statement (annual, 2022-12-31) — Depreciation Income Statement: 10243000.00
GENT.OL income_statement (annual, 2022-12-31) — Diluted Average Shares: 15422000.00
GENT.OL income_statement (annual, 2022-12-31) — Diluted EPS: -1.53
GENT.OL income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -23618000.00
GENT.OL income_statement (annual, 2022-12-31) — EBIT: -22363000.00
GENT.OL income_statement (annual, 2022-12-31) — EBITDA: -12120000.00
GENT.OL cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -395000.00
GENT.OL cash_flow (annual, 2022-12-31) — End Cash Position: 81599000.00
GENT.OL cash_flow (annual, 2022-12-31) — Financing Cash Flow: -4325000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Finished Goods: 5690000.00
GENT.OL cash_flow (annual, 2022-12-31) — Free Cash Flow: -28618000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 26820000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Gross PPE: 45751000.00
GENT.OL income_statement (annual, 2022-12-31) — Gross Profit: 49001000.00
GENT.OL income_statement (annual, 2022-12-31) — Interest Expense: 1255000.00
GENT.OL income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 1255000.00
GENT.OL income_statement (annual, 2022-12-31) — Interest Income: 1114000.00
GENT.OL income_statement (annual, 2022-12-31) — Interest Income Non Operating: 1114000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Inventories Adjustments Allowances: -925000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Inventory: 38544000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Invested Capital: 154170000.00
GENT.OL cash_flow (annual, 2022-12-31) — Investing Cash Flow: -14666000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 0.00
GENT.OL cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
GENT.OL cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
GENT.OL balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 11624000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 11624000.00
GENT.OL cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
GENT.OL cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -4325000.00
GENT.OL cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 0.00
GENT.OL cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
GENT.OL income_statement (annual, 2022-12-31) — Net Income: -23618000.00
GENT.OL income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -23618000.00
GENT.OL income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -23618000.00
GENT.OL income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -23618000.00
GENT.OL income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -23618000.00
GENT.OL cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -23618000.00
GENT.OL income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -23618000.00
GENT.OL cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -6029000.00
GENT.OL income_statement (annual, 2022-12-31) — Net Interest Income: -185000.00
GENT.OL cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -4325000.00
GENT.OL cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -4325000.00
GENT.OL income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -185000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Net PPE: 21637000.00
GENT.OL cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -8637000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 127350000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 0.00
GENT.OL income_statement (annual, 2022-12-31) — Normalized EBITDA: -12120000.00
GENT.OL income_statement (annual, 2022-12-31) — Normalized Income: -23618000.00
GENT.OL cash_flow (annual, 2022-12-31) — Operating Cash Flow: -13952000.00
GENT.OL income_statement (annual, 2022-12-31) — Operating Income: -23235000.00
GENT.OL income_statement (annual, 2022-12-31) — Operating Revenue: 101636000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 15422350.00
GENT.OL cash_flow (annual, 2022-12-31) — Other Cash Adjustment Outside Changein Cash: 1000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Current Assets: 1000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 8889000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Equity Interest: 1000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 26820000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Inventories: -1000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 1000.00
GENT.OL income_statement (annual, 2022-12-31) — Other Operating Expenses: 28029000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Properties: 45751000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Other Receivables: 9125000.00
GENT.OL income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
GENT.OL balance_sheet (annual, 2022-12-31) — Payables: 9408000.00
GENT.OL income_statement (annual, 2022-12-31) — Pretax Income: -23618000.00
GENT.OL cash_flow (annual, 2022-12-31) — Purchase Of Business: 0.00
GENT.OL cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -6029000.00
GENT.OL cash_flow (annual, 2022-12-31) — Purchase Of PPE: -8637000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Raw Materials: 16653000.00
GENT.OL income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 52635000.00
GENT.OL income_statement (annual, 2022-12-31) — Reconciled Depreciation: 10243000.00
GENT.OL income_statement (annual, 2022-12-31) — Rent And Landing Fees: 3287000.00
GENT.OL income_statement (annual, 2022-12-31) — Rent Expense Supplemental: 3287000.00
GENT.OL cash_flow (annual, 2022-12-31) — Repayment Of Debt: -4325000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Retained Earnings: -156477000.00
GENT.OL cash_flow (annual, 2022-12-31) — Sale Of Business: 0.00
GENT.OL income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 2390000.00
GENT.OL income_statement (annual, 2022-12-31) — Selling General And Administration: 2390000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Share Issued: 15422350.00
GENT.OL income_statement (annual, 2022-12-31) — Special Income Charges: 0.00
GENT.OL cash_flow (annual, 2022-12-31) — Stock Based Compensation: 3353000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Stockholders Equity: 154170000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Tangible Book Value: 127350000.00
GENT.OL income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
GENT.OL income_statement (annual, 2022-12-31) — Tax Provision: 0.00
GENT.OL income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.22
GENT.OL balance_sheet (annual, 2022-12-31) — Total Assets: 187790000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Total Capitalization: 154170000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Total Debt: 15323000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 154170000.00
GENT.OL income_statement (annual, 2022-12-31) — Total Expenses: 124871000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 33620000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 48458000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 11624000.00
GENT.OL income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -23235000.00
GENT.OL income_statement (annual, 2022-12-31) — Total Other Finance Cost: 44000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Total Tax Payable: 4965000.00
GENT.OL income_statement (annual, 2022-12-31) — Total Unusual Items: 0.00
GENT.OL income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 0.00
GENT.OL balance_sheet (annual, 2022-12-31) — Work In Process: 17127000.00
GENT.OL balance_sheet (annual, 2022-12-31) — Working Capital: 117336000.00
GENT.OL income_statement (annual, 2022-12-31) — Write Off: 0.00
GENT.OL income_statement (annual, 2023-12-31) — +Operating Expense: 77010000.00
GENT.OL income_statement (annual, 2023-12-31) — +Total Revenue: 135153000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Accounts Payable: 3706000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Accounts Receivable: 11569000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -30601000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 312142000.00
GENT.OL cash_flow (annual, 2023-12-31) — Amortization Cash Flow: 3078000.00
GENT.OL income_statement (annual, 2023-12-31) — Basic Average Shares: 15422000.00
GENT.OL income_statement (annual, 2023-12-31) — Basic EPS: -0.69
GENT.OL cash_flow (annual, 2023-12-31) — Beginning Cash Position: 81599000.00
GENT.OL cash_flow (annual, 2023-12-31) — Capital Expenditure: -4487000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 13049000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Capital Stock: 1542000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 87642000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 87642000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Cash Equivalents: 2277000.00
GENT.OL balance_sheet (annual, 2023-12-31) — Cash Financial: 85366000.00
GENT.OL cash_flow (annual, 2023-12-31) — Change In Inventory: 2692000.00